Genfit's Enrollment Delay In NASH May Aid Intercept's First-To-Market Goal

Firm cites heavy competition for NASH patients, as well as desire for balanced enrollment in elafibranor pivotal study. Competitor Intercept pushed back its Phase III enrollment timeline this past February.